首页 > 最新文献

Clinical Reviews in Allergy & Immunology最新文献

英文 中文
Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic Umbrella Review of the Evidence. 过敏性鼻炎的环境危险因素、保护因素和生物标志物:证据的系统综述。
IF 8.4 2区 医学 Q1 ALLERGY Pub Date : 2023-10-01 Epub Date: 2023-07-25 DOI: 10.1007/s12016-023-08964-2
Xianpeng Xu, Xinghong Liu, Jiongke Li, Xinxing Deng, Tianrong Dai, Qingjie Ji, Dajing Xiong, Hui Xie

Many potential environmental risk factors, protective factors, and biomarkers of AR have been published, but so far, the strength and consistency of their evidence are unclear. We conducted a comprehensive review of environmental risk, protective factors, and biomarkers for AR to establish the evidence hierarchy. We systematically searched Embase, PubMed, Cochrane Library, and Web of Science electronic database from inception to December 31, 2022. We calculated summary effect estimate (odds ratio (OR), relative risk (RR), hazard ratio (HR), and standardized mean difference (SMD)), 95% confidence interval, random effects p value, I2 statistic, 95% prediction interval, small study effects, and excess significance biases, and stratification of the level of evidence. Methodological quality was assessed by AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2). We retrieved 4478 articles, of which 43 met the inclusion criteria. The 43 eligible articles identified 31 potential environmental risk factors (10,806,206 total population, two study not reported), 11 potential environmental protective factors (823,883 total population), and 34 potential biomarkers (158,716 total population) for meta-analyses. The credibility of evidence was convincing (class I) for tic disorders (OR = 2.89, 95% CI 2.11-3.95); and highly suggestive (class II) for early-life antibiotic use (OR = 3.73, 95% CI 3.06-4.55), exposure to indoor dampness (OR = 1.49, 95% CI 1.27-1.75), acetaminophen exposure (OR = 1.54, 95% CI 1.41-1.69), childhood acid suppressant use (OR = 1.40, 95% CI 1.23-1.59), exposure to indoor mold (OR = 1.66, 95% CI 1.26-2.18), coronavirus disease 2019 (OR = 0.11, 95% CI 0.06-0.22), and prolonged breastfeeding (OR = 0.72, 95% CI 0.65-0.79). This study is registered in PROSPERO (CRD42022384320).

AR的许多潜在环境风险因素、保护因素和生物标志物已经发表,但到目前为止,它们的证据的强度和一致性尚不清楚。我们对AR的环境风险、保护因素和生物标志物进行了全面审查,以建立证据层次。从成立到2022年12月31日,我们系统地搜索了Embase、PubMed、Cochrane图书馆和Web of Science电子数据库。我们计算了汇总效应估计值(比值比(OR)、相对风险(RR)、危险比(HR)和标准化平均差(SMD))、95%置信区间、随机效应p值、I2统计量、95%预测区间、小研究效应和过度显著性偏差,以及证据水平的分层。方法学质量由AMSTAR 2(评估系统评价的测量工具2)进行评估。我们检索了4478篇文章,其中43篇符合纳入标准。43篇符合条件的文章确定了31个潜在环境风险因素(10806206个总人群,两项研究未报告)、11个潜在环境保护因素(823883个总人群)和34个潜在生物标志物(158716个总群体)用于荟萃分析。抽动障碍(OR)的证据可信度令人信服(I级) = 2.89、95%置信区间2.11-3.95);并且高度提示(II类)早期使用抗生素(OR = 3.73,95%可信区间3.06-4.55),暴露于室内潮湿(OR = 1.49,95%CI 1.27-1.75),对乙酰氨基酚暴露(OR = 1.54,95%可信区间1.41-1.69),儿童使用抑酸剂(OR = 1.40,95%置信区间1.23-1.59),暴露于室内霉菌(OR = 1.66,95%CI 1.26-2.18),2019冠状病毒病(OR = 0.11,95%可信区间0.06-0.22)和长期母乳喂养(OR = 0.72,95%CI 0.65-0.79)。本研究已在PROSPERO(CRD42022384320)注册。
{"title":"Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic Umbrella Review of the Evidence.","authors":"Xianpeng Xu, Xinghong Liu, Jiongke Li, Xinxing Deng, Tianrong Dai, Qingjie Ji, Dajing Xiong, Hui Xie","doi":"10.1007/s12016-023-08964-2","DOIUrl":"10.1007/s12016-023-08964-2","url":null,"abstract":"<p><p>Many potential environmental risk factors, protective factors, and biomarkers of AR have been published, but so far, the strength and consistency of their evidence are unclear. We conducted a comprehensive review of environmental risk, protective factors, and biomarkers for AR to establish the evidence hierarchy. We systematically searched Embase, PubMed, Cochrane Library, and Web of Science electronic database from inception to December 31, 2022. We calculated summary effect estimate (odds ratio (OR), relative risk (RR), hazard ratio (HR), and standardized mean difference (SMD)), 95% confidence interval, random effects p value, I<sup>2</sup> statistic, 95% prediction interval, small study effects, and excess significance biases, and stratification of the level of evidence. Methodological quality was assessed by AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2). We retrieved 4478 articles, of which 43 met the inclusion criteria. The 43 eligible articles identified 31 potential environmental risk factors (10,806,206 total population, two study not reported), 11 potential environmental protective factors (823,883 total population), and 34 potential biomarkers (158,716 total population) for meta-analyses. The credibility of evidence was convincing (class I) for tic disorders (OR = 2.89, 95% CI 2.11-3.95); and highly suggestive (class II) for early-life antibiotic use (OR = 3.73, 95% CI 3.06-4.55), exposure to indoor dampness (OR = 1.49, 95% CI 1.27-1.75), acetaminophen exposure (OR = 1.54, 95% CI 1.41-1.69), childhood acid suppressant use (OR = 1.40, 95% CI 1.23-1.59), exposure to indoor mold (OR = 1.66, 95% CI 1.26-2.18), coronavirus disease 2019 (OR = 0.11, 95% CI 0.06-0.22), and prolonged breastfeeding (OR = 0.72, 95% CI 0.65-0.79). This study is registered in PROSPERO (CRD42022384320).</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"188-205"},"PeriodicalIF":8.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9865917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypersensitivity Reactions to Taxanes: A Comprehensive and Systematic Review of the Efficacy and Safety of Desensitization. 紫杉烷的超敏反应:脱敏有效性和安全性的综合系统评价。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-10-01 Epub Date: 2023-08-17 DOI: 10.1007/s12016-023-08968-y
Rosalaura Virginia Villarreal-González, Sandra González-Díaz, Oscar Vidal-Gutiérrez, Alejandra Canel-Paredes, Carlos de la Cruz-de la Cruz, Mariano García-Campa, Alfonso López-Méndez, Sofía Alvarado-Ruiz, Mariana Castells

Taxanes in the treatment of cancer are associated with a significant incidence of hypersensitivity reactions, which may preclude their use in patients in need of first line therapy. Drug desensitization induces transient immunological tolerance and has allowed the reintroduction of taxanes in highly allergic patients. Increase the knowledge of hypersensitivity reactions (HSR) during the administration of taxanes. A systematic review regarding the safety and efficacy of rapid drug desensitization (RDD) for taxanes HSR. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was registered in PROSPERO(CRD42021242324) and a comprehensive search was conducted in Medline, Embase, Web of Science and Scopus databases. 25 studies encompassing 10 countries were identified and 976 patients with initial HSR to paclitaxel (n = 707) and docetaxel (n = 284), that underwent a total of 2,396 desensitizations. The most common symptoms were cutaneous (74.6%) with paclitaxel and respiratory (72.6%) with docetaxel. Severe initial hypersensitivity reactions including anaphylaxis occurred in 39.6% and 13% of paclitaxel and docetaxel cases respectively and during the first (87.4%) or second exposure (81.5%). Patients tolerated well RDD and breakthrough reactions (BTR) occurred in 32.2% of paclitaxel-treated patients and in 20.6% of docetaxel treated patients. Premedications included corticosteroids, antihistamines and leukotriene receptor antagonists. The most commonly used protocol was the BWH 3 bags 12 steps, all protocols showed a success rate between 95-100%, with no reported deaths. RDD is a safe and effective procedure in patients with HSR to taxanes and protocols should be standardized for wide range implementation.

紫杉烷在癌症治疗中与超敏反应的显著发生率相关,这可能会阻碍其在需要一线治疗的患者中的使用。药物脱敏诱导短暂的免疫耐受,并允许在高度过敏患者中重新引入紫杉烷。在服用紫杉烷期间增加对超敏反应(HSR)的了解。关于紫杉烷类HSR快速药物脱敏(RDD)的安全性和有效性的系统综述。该研究遵循了系统评价和荟萃分析的首选报告项目(PRISMA)指南,在PROSPERO(CRD42021242324)中注册,并在Medline、Embase、Web of Science和Scopus数据库中进行了全面搜索。确定了25项研究,涉及10个国家,976名紫杉醇初始HSR患者(n = 707)和多西他赛(n = 284),总共进行了2396次脱敏。最常见的症状是紫杉醇的皮肤症状(74.6%)和多西他赛的呼吸道症状(72.6%)。紫杉醇和多西他赛分别有39.6%和13%的患者在第一次(87.4%)或第二次暴露期间(81.5%)发生了包括过敏反应在内的严重初始超敏反应。32.2%的紫杉醇治疗患者和20.6%的多西他塞尔治疗患者对RDD和突破性反应(BTR)耐受良好。用药前包括皮质类固醇、抗组胺药和白三烯受体拮抗剂。最常用的方案是BWH 3袋12步,所有方案的成功率都在95-100%之间,没有死亡报告。RDD是治疗紫杉烷HSR患者的一种安全有效的方法,应将方案标准化以广泛实施。
{"title":"Hypersensitivity Reactions to Taxanes: A Comprehensive and Systematic Review of the Efficacy and Safety of Desensitization.","authors":"Rosalaura Virginia Villarreal-González,&nbsp;Sandra González-Díaz,&nbsp;Oscar Vidal-Gutiérrez,&nbsp;Alejandra Canel-Paredes,&nbsp;Carlos de la Cruz-de la Cruz,&nbsp;Mariano García-Campa,&nbsp;Alfonso López-Méndez,&nbsp;Sofía Alvarado-Ruiz,&nbsp;Mariana Castells","doi":"10.1007/s12016-023-08968-y","DOIUrl":"10.1007/s12016-023-08968-y","url":null,"abstract":"<p><p>Taxanes in the treatment of cancer are associated with a significant incidence of hypersensitivity reactions, which may preclude their use in patients in need of first line therapy. Drug desensitization induces transient immunological tolerance and has allowed the reintroduction of taxanes in highly allergic patients. Increase the knowledge of hypersensitivity reactions (HSR) during the administration of taxanes. A systematic review regarding the safety and efficacy of rapid drug desensitization (RDD) for taxanes HSR. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, was registered in PROSPERO(CRD42021242324) and a comprehensive search was conducted in Medline, Embase, Web of Science and Scopus databases. 25 studies encompassing 10 countries were identified and 976 patients with initial HSR to paclitaxel (n = 707) and docetaxel (n = 284), that underwent a total of 2,396 desensitizations. The most common symptoms were cutaneous (74.6%) with paclitaxel and respiratory (72.6%) with docetaxel. Severe initial hypersensitivity reactions including anaphylaxis occurred in 39.6% and 13% of paclitaxel and docetaxel cases respectively and during the first (87.4%) or second exposure (81.5%). Patients tolerated well RDD and breakthrough reactions (BTR) occurred in 32.2% of paclitaxel-treated patients and in 20.6% of docetaxel treated patients. Premedications included corticosteroids, antihistamines and leukotriene receptor antagonists. The most commonly used protocol was the BWH 3 bags 12 steps, all protocols showed a success rate between 95-100%, with no reported deaths. RDD is a safe and effective procedure in patients with HSR to taxanes and protocols should be standardized for wide range implementation.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"231-250"},"PeriodicalIF":9.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10014835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Food Allergy Labeling Laws: International Guidelines for Residents and Travelers. 《食品过敏标签法:居民和旅行者国际指南》。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-10-01 Epub Date: 2023-05-09 DOI: 10.1007/s12016-023-08960-6
Francesca Chang, Lauren Eng, Christopher Chang

The prevalence of food allergies varies by country, as does each country's food allergen labeling. While labeling laws may vary by country, most follow the Codex Alimentarius. Even developing countries have some degree of labeling guidelines for food allergies, but it is highly developed countries that tend to implement stricter labeling regulations to protect their citizens and tourists. Different organizations, both domestic and international, such as Food Allergy Research and Education (FARE), work to advance food allergen labeling laws around the globe. Eating out and traveling can be anxiety-provoking for people with food allergies, especially when traveling to international destinations. Furthermore, experiences that young children, teenagers, and parents have with food allergies can have psychosocial and social impacts. To evaluate food allergen labeling laws across the globe, official legal documents outlining the laws pertaining to foods and allergen food labeling were reviewed for each respective country or region. These were organized according to continent, then region or country. The majority of countries require that major food groups be listed on food labels, including milk, egg, soy, wheat, peanuts, treenuts, fish, and shellfish. There are individual variations across regions depending on staples in respective diets. With increasing rates of food allergies worldwide, legislative action is needed to ensure that people living with food allergies can more safely purchase and consume foods. Until then, the work of avoiding accidental ingestions and anaphylaxis remains primarily with the individual, who must educate themselves on labeling laws and implement other protective measures.

食物过敏的流行率因国家而异,每个国家的食物过敏原标签也是如此。虽然各国的标签法可能有所不同,但大多数都遵循食品法典。即使是发展中国家也有一定程度的食品过敏标签指南,但正是高度发达的国家倾向于实施更严格的标签规定,以保护其公民和游客。国内外不同的组织,如食品过敏研究与教育组织,致力于在全球范围内推进食品过敏原标签法。对于食物过敏的人来说,外出就餐和旅行可能会引发焦虑,尤其是在前往国际目的地时。此外,幼儿、青少年和父母对食物过敏的经历可能会产生心理社会影响。为了评估全球范围内的食品过敏原标签法,审查了每个国家或地区概述食品和过敏原食品标签相关法律的官方法律文件。这些是根据大陆、地区或国家组织的。大多数国家要求在食品标签上列出主要食品类别,包括牛奶、鸡蛋、大豆、小麦、花生、坚果、鱼类和贝类。不同地区的个体差异取决于各自饮食中的主食。随着全球食物过敏率的上升,需要采取立法行动,确保食物过敏患者能够更安全地购买和食用食物。在此之前,避免意外摄入和过敏反应的工作主要由个人完成,他们必须自学标签法并实施其他保护措施。
{"title":"Food Allergy Labeling Laws: International Guidelines for Residents and Travelers.","authors":"Francesca Chang,&nbsp;Lauren Eng,&nbsp;Christopher Chang","doi":"10.1007/s12016-023-08960-6","DOIUrl":"10.1007/s12016-023-08960-6","url":null,"abstract":"<p><p>The prevalence of food allergies varies by country, as does each country's food allergen labeling. While labeling laws may vary by country, most follow the Codex Alimentarius. Even developing countries have some degree of labeling guidelines for food allergies, but it is highly developed countries that tend to implement stricter labeling regulations to protect their citizens and tourists. Different organizations, both domestic and international, such as Food Allergy Research and Education (FARE), work to advance food allergen labeling laws around the globe. Eating out and traveling can be anxiety-provoking for people with food allergies, especially when traveling to international destinations. Furthermore, experiences that young children, teenagers, and parents have with food allergies can have psychosocial and social impacts. To evaluate food allergen labeling laws across the globe, official legal documents outlining the laws pertaining to foods and allergen food labeling were reviewed for each respective country or region. These were organized according to continent, then region or country. The majority of countries require that major food groups be listed on food labels, including milk, egg, soy, wheat, peanuts, treenuts, fish, and shellfish. There are individual variations across regions depending on staples in respective diets. With increasing rates of food allergies worldwide, legislative action is needed to ensure that people living with food allergies can more safely purchase and consume foods. Until then, the work of avoiding accidental ingestions and anaphylaxis remains primarily with the individual, who must educate themselves on labeling laws and implement other protective measures.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"148-165"},"PeriodicalIF":9.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9505127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
During Sepsis and COVID-19, the Pro-Inflammatory and Anti-Inflammatory Responses Are Concomitant. 脓毒症和新冠肺炎期间,促炎和抗炎反应是伴随的。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-10-01 Epub Date: 2023-07-03 DOI: 10.1007/s12016-023-08965-1
Jean-Marc Cavaillon

The most severe forms of COVID-19 share many features with bacterial sepsis and have thus been considered to be a viral sepsis. Innate immunity and inflammation are closely linked. While the immune response aims to get rid of the infectious agent, the pro-inflammatory host response can result in organ injury including acute respiratory distress syndrome. On its side, a compensatory anti-inflammatory response, aimed to dampen the inflammatory reaction, can lead to immunosuppression. Whether these two key events of the host inflammatory response are consecutive or concomitant has been regularly depicted in schemes. Initially proposed from 2001 to 2013 to be two consecutive steps, the concomitant occurrence has been supported since 2013, although it was proposed for the first time in 2001. Despite a consensus was reached, the two consecutive steps were still recently proposed for COVID-19. We discuss why the concomitance view could have been initiated as early as 1995.

新冠肺炎最严重的形式与细菌性败血症有许多共同特征,因此被认为是一种病毒性败血症。先天免疫与炎症密切相关。虽然免疫反应旨在清除传染源,但促炎宿主反应可能导致器官损伤,包括急性呼吸窘迫综合征。另一方面,旨在抑制炎症反应的补偿性抗炎反应可能导致免疫抑制。宿主炎症反应的这两个关键事件是连续的还是伴随的,已经在方案中定期描述。最初提议从2001年到2013年是两个连续的步骤,自2013年以来,伴随出现的情况一直得到支持,尽管2001年首次提出。尽管达成了共识,但最近仍针对新冠肺炎提出了两个连续步骤。我们讨论了为什么伴随观点最早可以在1995年提出。
{"title":"During Sepsis and COVID-19, the Pro-Inflammatory and Anti-Inflammatory Responses Are Concomitant.","authors":"Jean-Marc Cavaillon","doi":"10.1007/s12016-023-08965-1","DOIUrl":"10.1007/s12016-023-08965-1","url":null,"abstract":"<p><p>The most severe forms of COVID-19 share many features with bacterial sepsis and have thus been considered to be a viral sepsis. Innate immunity and inflammation are closely linked. While the immune response aims to get rid of the infectious agent, the pro-inflammatory host response can result in organ injury including acute respiratory distress syndrome. On its side, a compensatory anti-inflammatory response, aimed to dampen the inflammatory reaction, can lead to immunosuppression. Whether these two key events of the host inflammatory response are consecutive or concomitant has been regularly depicted in schemes. Initially proposed from 2001 to 2013 to be two consecutive steps, the concomitant occurrence has been supported since 2013, although it was proposed for the first time in 2001. Despite a consensus was reached, the two consecutive steps were still recently proposed for COVID-19. We discuss why the concomitance view could have been initiated as early as 1995.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"183-187"},"PeriodicalIF":9.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatable Traits in Systemic Sclerosis. 系统性硬化症的可治疗特征。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-10-01 Epub Date: 2023-08-21 DOI: 10.1007/s12016-023-08969-x
Francesco Amati, Gabriele Bongiovanni, Antonio Tonutti, Francesca Motta, Anna Stainer, Giuseppe Mangiameli, Stefano Aliberti, Carlo Selmi, Maria De Santis

Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high morbidity and mortality. The clinical phenotype of SSc is heterogeneous, and serum autoantibodies together with the extent of skin involvement have a predictive value in the risk stratification. Current recommendations include an organ-based management according to the predominant involvement with only limited individual factors included in the treatment algorithm. Similar to what has been proposed for other chronic diseases, we hypothesize that a "treatable trait" approach based on relevant phenotypes and endotypes could address the unmet needs in SSc stratification and treatment to maximize the outcomes. We provide herein a comprehensive review and a critical discussion of the literature regarding potential treatable traits in SSc, focusing on established and candidate biomarkers, with the purpose of setting the bases for a precision medicine-based approach. The discussion, structured based on the organ involvement, allows to conjugate the pathogenetic mechanisms of tissue injury with the proposed predictors, particularly autoantibodies and other serum biomarkers. Ultimately, we are convinced that precision medicine is the ideal guide to manage a complex condition such as SSc for which available treatments are largely unsatisfactory.

系统性硬化症(SSc)是结缔组织疾病中的一种慢性系统性疾病,其特征是血管异常以及皮肤和内脏的炎症和纤维化,导致高发病率和高死亡率。SSc的临床表型是异质性的,血清自身抗体和皮肤受累程度在风险分层中具有预测价值。目前的建议包括根据主要参与程度进行基于器官的管理,治疗算法中仅包括有限的个体因素。与针对其他慢性病的建议类似,我们假设基于相关表型和内型的“可治疗特征”方法可以解决SSc分层和治疗中未满足的需求,以最大限度地提高结果。我们在本文中对SSc潜在可治疗特征的文献进行了全面综述和批判性讨论,重点关注已建立的和候选的生物标志物,目的是为基于精准医学的方法奠定基础。基于器官受累的讨论,可以将组织损伤的发病机制与所提出的预测因素结合起来,特别是自身抗体和其他血清生物标志物。最终,我们相信,精准医学是治疗SSc等复杂疾病的理想指南,而现有的治疗方法在很大程度上并不令人满意。
{"title":"Treatable Traits in Systemic Sclerosis.","authors":"Francesco Amati,&nbsp;Gabriele Bongiovanni,&nbsp;Antonio Tonutti,&nbsp;Francesca Motta,&nbsp;Anna Stainer,&nbsp;Giuseppe Mangiameli,&nbsp;Stefano Aliberti,&nbsp;Carlo Selmi,&nbsp;Maria De Santis","doi":"10.1007/s12016-023-08969-x","DOIUrl":"10.1007/s12016-023-08969-x","url":null,"abstract":"<p><p>Systemic sclerosis (SSc) is a chronic systemic disease within the spectrum of connective tissue diseases, specifically characterized by vascular abnormalities and inflammatory and fibrotic involvement of the skin and internal organs resulting in high morbidity and mortality. The clinical phenotype of SSc is heterogeneous, and serum autoantibodies together with the extent of skin involvement have a predictive value in the risk stratification. Current recommendations include an organ-based management according to the predominant involvement with only limited individual factors included in the treatment algorithm. Similar to what has been proposed for other chronic diseases, we hypothesize that a \"treatable trait\" approach based on relevant phenotypes and endotypes could address the unmet needs in SSc stratification and treatment to maximize the outcomes. We provide herein a comprehensive review and a critical discussion of the literature regarding potential treatable traits in SSc, focusing on established and candidate biomarkers, with the purpose of setting the bases for a precision medicine-based approach. The discussion, structured based on the organ involvement, allows to conjugate the pathogenetic mechanisms of tissue injury with the proposed predictors, particularly autoantibodies and other serum biomarkers. Ultimately, we are convinced that precision medicine is the ideal guide to manage a complex condition such as SSc for which available treatments are largely unsatisfactory.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"251-276"},"PeriodicalIF":9.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10022959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
COVID-19, Coronavirus Vaccines, and Possible Association with Lipschütz Vulvar Ulcer: A Systematic Review. 新冠肺炎,冠状病毒疫苗,以及与Lipschütz Vulvar溃疡的可能关联:系统综述。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-10-01 Epub Date: 2023-06-26 DOI: 10.1007/s12016-023-08961-5
Stefano A Vismara, Andrea Ridolfi, Pietro B Faré, Mario G Bianchetti, Sebastiano A G Lava, Samuele Renzi, Benedetta Terziroli Beretta Piccoli, Gregorio P Milani, Lisa Kottanattu

Lipschütz genital ulcer is a self-limited, non-sexually acquired disorder characterized by the sudden onset of a few ulcers. A primary Epstein-Barr virus infection is currently considered the most recognized cause. Recent reports document cases temporally related with coronavirus disease 2019 (COVID-19) or immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We carried out a review of the literature to investigate the possible association between COVID-19 or the immunization against SARS-CoV-2 and genital ulcer. The pre-registered study (CRD42023376260) was undertaken following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology. Excerpta Medica, the National Library of Medicine, and Web of Sciences were searched. Inclusion criteria encompassed instances of acute Lipschütz ulcer episodes that were temporally linked to either COVID-19 or a vaccination against SARS-CoV-2. Eighteen articles were retained. They provided information on 33 patients 15 (14-24) years of age (median and interquartile range), who experienced a total of 39 episodes of Lipschütz ulcer temporally associated with COVID-19 (N = 18) or an immunization against SARS-CoV-2 (N = 21). The possible concomitant existence of an acute Epstein-Barr virus infection was excluded in 30 of the 39 episodes. The clinical presentation and the disease duration were similar in episodes temporally associated with COVID-19 and in those associated with an immunization against SARS-CoV-2. In conclusion, COVID-19 and immunization against SARS-CoV-2 add to Epstein-Barr virus as plausible triggers of Lipschütz genital ulcer.

Lipschütz生殖器溃疡是一种自我限制的非性获得性疾病,其特征是突然发作一些溃疡。原发性EB病毒感染目前被认为是最公认的病因。最近的报告记录了与2019冠状病毒病(新冠肺炎)或严重急性呼吸综合征冠状病毒2(SARS-CoV-2)免疫接种暂时相关的病例。我们对文献进行了回顾,以调查新冠肺炎或针对SARS-CoV-2的免疫接种与生殖器溃疡之间的可能关联。预注册研究(CRD42023376260)按照系统评价和荟萃分析方法的首选报告项目进行。《医学文摘》、《国家医学图书馆》和《科学网》被搜索到。纳入标准包括与新冠肺炎或接种SARS-CoV-2疫苗暂时相关的急性Lipschütz溃疡发作。保留了18条。他们提供了33名15(14-24)岁(中位数和四分位间距)患者的信息,这些患者共经历了39次与新冠肺炎暂时相关的Lipschütz溃疡发作(N = 18) 或针对严重急性呼吸系统综合征冠状病毒2型(N = 21)。39次发作中有30次排除了可能同时存在急性爱泼斯坦-巴尔病毒感染。与新冠肺炎暂时相关的发作和与针对SARS-CoV-2的免疫相关的发作的临床表现和疾病持续时间相似。总之,新冠肺炎和针对SARS-CoV-2的免疫接种增加了Epstein-Barr病毒,成为Lipschütz生殖器溃疡的可能触发因素。
{"title":"COVID-19, Coronavirus Vaccines, and Possible Association with Lipschütz Vulvar Ulcer: A Systematic Review.","authors":"Stefano A Vismara,&nbsp;Andrea Ridolfi,&nbsp;Pietro B Faré,&nbsp;Mario G Bianchetti,&nbsp;Sebastiano A G Lava,&nbsp;Samuele Renzi,&nbsp;Benedetta Terziroli Beretta Piccoli,&nbsp;Gregorio P Milani,&nbsp;Lisa Kottanattu","doi":"10.1007/s12016-023-08961-5","DOIUrl":"10.1007/s12016-023-08961-5","url":null,"abstract":"<p><p>Lipschütz genital ulcer is a self-limited, non-sexually acquired disorder characterized by the sudden onset of a few ulcers. A primary Epstein-Barr virus infection is currently considered the most recognized cause. Recent reports document cases temporally related with coronavirus disease 2019 (COVID-19) or immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We carried out a review of the literature to investigate the possible association between COVID-19 or the immunization against SARS-CoV-2 and genital ulcer. The pre-registered study (CRD42023376260) was undertaken following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology. Excerpta Medica, the National Library of Medicine, and Web of Sciences were searched. Inclusion criteria encompassed instances of acute Lipschütz ulcer episodes that were temporally linked to either COVID-19 or a vaccination against SARS-CoV-2. Eighteen articles were retained. They provided information on 33 patients 15 (14-24) years of age (median and interquartile range), who experienced a total of 39 episodes of Lipschütz ulcer temporally associated with COVID-19 (N = 18) or an immunization against SARS-CoV-2 (N = 21). The possible concomitant existence of an acute Epstein-Barr virus infection was excluded in 30 of the 39 episodes. The clinical presentation and the disease duration were similar in episodes temporally associated with COVID-19 and in those associated with an immunization against SARS-CoV-2. In conclusion, COVID-19 and immunization against SARS-CoV-2 add to Epstein-Barr virus as plausible triggers of Lipschütz genital ulcer.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"166-171"},"PeriodicalIF":9.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9683874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmunity in Primary Immunodeficiencies (PID). 原发性免疫缺陷(PID)的自身免疫。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-08-01 DOI: 10.1007/s12016-022-08942-0
Grace T Padron, Vivian P Hernandez-Trujillo

Primary immunodeficiency (PID) may impact any component of the immune system. The number of PID and immune dysregulation disorders is growing steadily with advancing genetic detection methods. These expansive recognition methods have changed the way we characterize PID. While PID were once characterized by their susceptibility to infection, the increase in genetic analysis has elucidated the intertwined relationship between PID and non-infectious manifestations including autoimmunity. The defects permitting opportunistic infections to take hold may also lead the way to the development of autoimmune disease. In some cases, it is the non-infectious complications that may be the presenting sign of PID autoimmune diseases, such as autoimmune cytopenia, enteropathy, endocrinopathies, and arthritis among others, have been reported in PID. While autoimmunity may occur with any PID, this review will look at certain immunodeficiencies most often associated with autoimmunity, as well as their diagnosis and management strategies.

原发性免疫缺陷(PID)可能影响免疫系统的任何组成部分。随着基因检测方法的进步,PID和免疫失调疾病的数量正在稳步增长。这些广泛的识别方法已经改变了我们描述PID的方式。虽然PID曾经以其对感染的易感性为特征,但遗传分析的增加已经阐明了PID与非感染性表现(包括自身免疫)之间的相互交织关系。允许机会性感染的缺陷也可能导致自身免疫性疾病的发展。在某些情况下,非感染性并发症可能是PID自身免疫性疾病的表现,如自身免疫性细胞减少症、肠病、内分泌病和关节炎等,在PID中已被报道。虽然任何PID都可能发生自身免疫,但本综述将着眼于某些与自身免疫最相关的免疫缺陷,以及它们的诊断和管理策略。
{"title":"Autoimmunity in Primary Immunodeficiencies (PID).","authors":"Grace T Padron,&nbsp;Vivian P Hernandez-Trujillo","doi":"10.1007/s12016-022-08942-0","DOIUrl":"https://doi.org/10.1007/s12016-022-08942-0","url":null,"abstract":"<p><p>Primary immunodeficiency (PID) may impact any component of the immune system. The number of PID and immune dysregulation disorders is growing steadily with advancing genetic detection methods. These expansive recognition methods have changed the way we characterize PID. While PID were once characterized by their susceptibility to infection, the increase in genetic analysis has elucidated the intertwined relationship between PID and non-infectious manifestations including autoimmunity. The defects permitting opportunistic infections to take hold may also lead the way to the development of autoimmune disease. In some cases, it is the non-infectious complications that may be the presenting sign of PID autoimmune diseases, such as autoimmune cytopenia, enteropathy, endocrinopathies, and arthritis among others, have been reported in PID. While autoimmunity may occur with any PID, this review will look at certain immunodeficiencies most often associated with autoimmunity, as well as their diagnosis and management strategies.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":"65 1","pages":"1-18"},"PeriodicalIF":9.1,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9774978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The Treatment of Primary Immune Deficiencies: Lessons Learned and Future Opportunities. 原发性免疫缺陷的治疗:经验教训与未来机遇。
IF 8.4 2区 医学 Q1 ALLERGY Pub Date : 2023-08-01 Epub Date: 2022-07-01 DOI: 10.1007/s12016-022-08950-0
Kenneth Paris, Luke A Wall

Primary immunodeficiency is a group of disorders associated with susceptibility to infectious agents and the development of various comorbidities. Many primary immunodeficiencies are complicated by immune dysregulation, autoinflammation, or autoimmunity which impacts multiple organ systems. Major advances in the treatment of these disorders have occurred over the last half-century, and deeper molecular understanding of many disorders combined with clinically available genetic testing is allowing for use of precision therapy for several primary immunodeficiencies. Patients with antibody deficiencies who rely on immunoglobulin replacement therapy now have many treatment options with products that are much safer and better tolerated compared to the past. Newborn screening for severe combined immunodeficiency, now implemented throughout the USA and in many countries worldwide, has lowered the age at which many patients are diagnosed with these diseases. Early diagnosis of severe combined immunodeficiency allows infants to proceed to definitive therapy such as stem cell transplantation or gene therapy prior to facing potentially life-threatening infections. While stem cell transplantation continues to carry significant risks, knowledge gained over recent decades is allowing for improved survival with less toxicity and less graft versus host disease.

原发性免疫缺陷是一组与易感染传染病病原体和出现各种合并症有关的疾病。许多原发性免疫缺陷并发免疫失调、自身炎症或自身免疫,影响多个器官系统。在过去的半个世纪中,这些疾病的治疗取得了重大进展,对许多疾病更深入的分子认识与临床上可用的基因检测相结合,使精准治疗在一些原发性免疫缺陷症中得以应用。依靠免疫球蛋白替代疗法的抗体缺乏症患者现在有了许多治疗选择,与过去相比,这些产品更加安全,耐受性更好。新生儿重症联合免疫缺陷筛查目前已在美国和世界许多国家实施,降低了许多患者被诊断出这些疾病的年龄。重症联合免疫缺陷症的早期诊断可以让婴儿在面临可能危及生命的感染之前,接受干细胞移植或基因治疗等明确的治疗。虽然干细胞移植仍有很大风险,但近几十年来获得的知识使移植后的存活率提高,毒性降低,移植物抗宿主疾病减少。
{"title":"The Treatment of Primary Immune Deficiencies: Lessons Learned and Future Opportunities.","authors":"Kenneth Paris, Luke A Wall","doi":"10.1007/s12016-022-08950-0","DOIUrl":"10.1007/s12016-022-08950-0","url":null,"abstract":"<p><p>Primary immunodeficiency is a group of disorders associated with susceptibility to infectious agents and the development of various comorbidities. Many primary immunodeficiencies are complicated by immune dysregulation, autoinflammation, or autoimmunity which impacts multiple organ systems. Major advances in the treatment of these disorders have occurred over the last half-century, and deeper molecular understanding of many disorders combined with clinically available genetic testing is allowing for use of precision therapy for several primary immunodeficiencies. Patients with antibody deficiencies who rely on immunoglobulin replacement therapy now have many treatment options with products that are much safer and better tolerated compared to the past. Newborn screening for severe combined immunodeficiency, now implemented throughout the USA and in many countries worldwide, has lowered the age at which many patients are diagnosed with these diseases. Early diagnosis of severe combined immunodeficiency allows infants to proceed to definitive therapy such as stem cell transplantation or gene therapy prior to facing potentially life-threatening infections. While stem cell transplantation continues to carry significant risks, knowledge gained over recent decades is allowing for improved survival with less toxicity and less graft versus host disease.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":"65 1","pages":"19-30"},"PeriodicalIF":8.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9775453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vernal Keratoconjunctivitis: A Systematic Review. 春季角膜结膜炎:一项系统综述。
IF 8.4 2区 医学 Q1 ALLERGY Pub Date : 2023-08-01 Epub Date: 2023-09-02 DOI: 10.1007/s12016-023-08970-4
Gaia Bruschi, Daniele Giovanni Ghiglioni, Laura Cozzi, Silvia Osnaghi, Francesco Viola, Paola Marchisio

Vernal keratoconjunctivitis (VKC) is a chronic, bilateral corneal and conjunctival problem which typically presents in young individuals. VKC is characterized by itching, photophobia, white mucous discharge, lacrimation, foreign body sensation, and pain due to corneal involvement of shield ulcers. Vernal keratoconjunctivitis is categorized within ocular diseases. The diagnosis is clinical, as no sure biomarkers pathognomonic of the disease have yet been identified. The VKC therapy relies on different types of drugs, from antihistamines and topical steroids to cyclosporine or tacrolimus eye drops. In extremely rare cases, there is also the need for surgical treatment for the debridement of ulcers, as well as for advanced glaucoma and cataracts, caused by excessive prolonged use of steroid eye drops. We performed a systematic review of the literature, according to PRISMA guideline recommendations. We searched the PubMed database from January 2016 to June 2023. Search terms were Vernal, Vernal keratoconjunctivitis, and VKC. We initially identified 211 articles. After the screening process, 168 studies were eligible according to our criteria and were included in the review. In this study, we performed a systematic literature review to provide a comprehensive overview of currently available diagnostic methods, management of VKC, and its treatments.

春季角结膜炎(VKC)是一种慢性双侧角膜和结膜问题,通常发生在年轻人身上。VKC的特征是瘙痒、畏光、白色粘液分泌物、流泪、异物感和因角膜溃疡引起的疼痛。春季角结膜炎属于眼部疾病。诊断是临床的,因为还没有确定该疾病的病理标志物。VKC疗法依赖于不同类型的药物,从抗组胺药和局部类固醇到环孢素或他克莫司滴眼液。在极少数情况下,还需要对溃疡清创术以及因过度长期使用类固醇滴眼液而引起的晚期青光眼和白内障进行手术治疗。根据PRISMA指南的建议,我们对文献进行了系统回顾。我们搜索了PubMed数据库,时间为2016年1月至2023年6月。搜索词为Vernal、Vernal角结膜炎和VKC。我们最初确定了211篇文章。筛选过程结束后,168项研究符合我们的标准,并被纳入审查。在这项研究中,我们进行了一项系统的文献综述,以全面概述目前可用的诊断方法、VKC的管理及其治疗。
{"title":"Vernal Keratoconjunctivitis: A Systematic Review.","authors":"Gaia Bruschi, Daniele Giovanni Ghiglioni, Laura Cozzi, Silvia Osnaghi, Francesco Viola, Paola Marchisio","doi":"10.1007/s12016-023-08970-4","DOIUrl":"10.1007/s12016-023-08970-4","url":null,"abstract":"<p><p>Vernal keratoconjunctivitis (VKC) is a chronic, bilateral corneal and conjunctival problem which typically presents in young individuals. VKC is characterized by itching, photophobia, white mucous discharge, lacrimation, foreign body sensation, and pain due to corneal involvement of shield ulcers. Vernal keratoconjunctivitis is categorized within ocular diseases. The diagnosis is clinical, as no sure biomarkers pathognomonic of the disease have yet been identified. The VKC therapy relies on different types of drugs, from antihistamines and topical steroids to cyclosporine or tacrolimus eye drops. In extremely rare cases, there is also the need for surgical treatment for the debridement of ulcers, as well as for advanced glaucoma and cataracts, caused by excessive prolonged use of steroid eye drops. We performed a systematic review of the literature, according to PRISMA guideline recommendations. We searched the PubMed database from January 2016 to June 2023. Search terms were Vernal, Vernal keratoconjunctivitis, and VKC. We initially identified 211 articles. After the screening process, 168 studies were eligible according to our criteria and were included in the review. In this study, we performed a systematic literature review to provide a comprehensive overview of currently available diagnostic methods, management of VKC, and its treatments.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"277-329"},"PeriodicalIF":8.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10146311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
γδ T Cells and Allergic Diseases. γδT细胞与变态反应性疾病。
IF 9.1 2区 医学 Q1 ALLERGY Pub Date : 2023-08-01 Epub Date: 2023-07-03 DOI: 10.1007/s12016-023-08966-0
Uei-Hsiang Hsu, Bor-Luen Chiang

Gamma-delta (γδ) T cells play an essential role in allergic diseases and have emerged as a potential treatment target in recent decades. To clarify the effects of γδ T cells on atopic illnesses, we reviewed the literature on the physical roles and functions of various subsets of γδ T cells, including type 1 T helper (Th1)-like, type 2 T helper- (Th2)-like, and type 17 T helper (Th17)-like γδ T cells. Mouse Vγ1 T cells increase interleukin (IL)-4 levels and trigger B cell class switching and immunoglobulin E production. Meanwhile, mouse Vγ4 T cells and human CD8lowVδ1 T cells secrete interferon-γ and exert an anti-allergy effect similar to that of Th1 cells. Moreover, mouse Vγ6 T cells produce IL-17A, while Th17-like γδ T cells enhance neutrophil and eosinophil infiltration in the acute phase of inflammation, but exert anti-inflammatory effects in the chronic phase. Human Vγ9δ2 T cells may exhibit Th1- or Th2-like characteristics in response to certain types of stimulation. In addition, the microbiota can modulate epithelial γδ T cell survival through aryl hydrocarbon receptors; these γδ T cells play crucial roles in the repair of epithelial damage, antibacterial protection, antigen tolerance, and effects of dysbiosis on allergic diseases.

γδT细胞在过敏性疾病中发挥着重要作用,近几十年来已成为潜在的治疗靶点。为了阐明γδT细胞在特应性疾病中的作用,我们回顾了关于γδT淋巴细胞各亚群的物理作用和功能的文献,包括1型辅助性T细胞(Th1)样、2型辅助性T细胞(Th2)样和17型辅助性特应性T细胞。小鼠Vγ1 T细胞增加白细胞介素(IL)-4水平并触发B细胞类别转换和免疫球蛋白E的产生。同时,小鼠Vγ4 T细胞和人CD8lowVδ1 T细胞分泌干扰素-γ,并发挥类似于Th1细胞的抗过敏作用。此外,小鼠Vγ6 T细胞产生IL-17A,而Th17样γδT细胞在炎症的急性期增强中性粒细胞和嗜酸性粒细胞的浸润,但在慢性期发挥抗炎作用。人Vγ9δ2 T细胞可能对某些类型的刺激表现出Th1或Th2样特征。此外,微生物群可以通过芳烃受体调节上皮γδT细胞的存活;这些γδT细胞在修复上皮损伤、抗菌保护、抗原耐受以及微生态失调对过敏性疾病的影响中发挥着至关重要的作用。
{"title":"γδ T Cells and Allergic Diseases.","authors":"Uei-Hsiang Hsu,&nbsp;Bor-Luen Chiang","doi":"10.1007/s12016-023-08966-0","DOIUrl":"10.1007/s12016-023-08966-0","url":null,"abstract":"<p><p>Gamma-delta (γδ) T cells play an essential role in allergic diseases and have emerged as a potential treatment target in recent decades. To clarify the effects of γδ T cells on atopic illnesses, we reviewed the literature on the physical roles and functions of various subsets of γδ T cells, including type 1 T helper (Th1)-like, type 2 T helper- (Th2)-like, and type 17 T helper (Th17)-like γδ T cells. Mouse Vγ1 T cells increase interleukin (IL)-4 levels and trigger B cell class switching and immunoglobulin E production. Meanwhile, mouse Vγ4 T cells and human CD8<sup>low</sup>Vδ1 T cells secrete interferon-γ and exert an anti-allergy effect similar to that of Th1 cells. Moreover, mouse Vγ6 T cells produce IL-17A, while Th17-like γδ T cells enhance neutrophil and eosinophil infiltration in the acute phase of inflammation, but exert anti-inflammatory effects in the chronic phase. Human Vγ9δ2 T cells may exhibit Th1- or Th2-like characteristics in response to certain types of stimulation. In addition, the microbiota can modulate epithelial γδ T cell survival through aryl hydrocarbon receptors; these γδ T cells play crucial roles in the repair of epithelial damage, antibacterial protection, antigen tolerance, and effects of dysbiosis on allergic diseases.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":" ","pages":"172-182"},"PeriodicalIF":9.1,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10116601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Reviews in Allergy & Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1